Podcasts about life sciences

Hey hey—it's Friday, it's Halloween, and it's time for another round of Stoppage Time with Uncle Rob!In this week's episode, I'm catching up on life, reflecting on Halloween traditions (past and future), and diving deep into the week that was—new Entrepreneurial Thinkers episodes, big developments in California's booming Life Sciences industry, and some personal thoughts on creativity, purpose, and what's next for this very show.You'll hear about my recent conversation with my good friend (and show alum) Dave Whelan as we explore how massive investments and new innovation hubs are shaping the future of Life Sciences in Los Angeles—and how that's changing the way we'll all live and thrive in the years ahead.Beyond that, it's one of those laid-back, honest Fridays where we take a step back and ask: What's this show really about? Has it evolved, or is it ready to evolve again? And how can we make it even more valuable or inspiring for you—our listeners and friends?So grab a coffee (or maybe a little leftover Halloween candy), settle in, and join me for another thoughtful, unscripted hangout full of reflection, inspiration, and a touch of weekend energy.

On the Thursday, Oct. 30 edition of Georgia Today: The parent company of Georgia Power beats Wall Street expectations; Gwinnett County will soon get a new life sciences research park; and frustration builds as the government shutdown continues.

Is our Life Sciences industry the most under-reported unicorn in California's industrial dominance? Can Life Sciences innovation survive the USA government's assault on science? In this eye-opening episode, Rob sits down with friend Dave Whelan, to uncover how LA is rapidly transforming into a major player in biotech and health innovation. They discuss groundbreaking projects like UCLA's new Research Park, the explosion of AI in drug discovery, and how diversity and storytelling are shaping the future of healthcare and life sciences startups. From political roadblocks to billion-dollar opportunities, this conversation is packed with insights for anyone curious about where health tech is heading—and why LA might just be leading the charge.Feel free to follow and engage with DAVE here:LinkedIn: https://www.linkedin.com/in/djwhelan/Instagram: https://www.instagram.com/djwhelanX: https://x.com/djwhelanFacebook: https://www.facebook.com/djwhelanWebsite: https://www.bespokestrategy.com/whelanWe're so grateful to you, our growing audience of entrepreneurs, investors and community leaders interested in the human stories of the Entrepreneurial Thinkers behind entrepreneurial economies worldwide.As always we hope you enjoy each episode and Like, Follow, Subscribe or share with your friends. You can find our shows here, and our new Video Podcast, at “Entrepreneurial Thinkers” channel on YouTube. Plug in, relax and enjoy inspiring, educational and empowering conversations between Rob and our guests.¡Cheers y gracias!,Entrepreneurial Thinkers Team.Chapters00:00 Introduction to Entrepreneurial Thinkers04:46 The Evolution of Life Sciences in California19:03 UCLA Research Park: A New Era for Innovation28:37 The Vision for Life Sciences Development33:31 The Role of Universities in Life Sciences37:23 Navigating Funding Challenges in Academia47:03 Breakthroughs in Life Sciences and AI's Impact56:55 Understanding Neurodegenerative Diseases58:47 Diversity in Innovation and Health Sciences01:06:37 The Importance of Storytelling in Health Tech01:11:56 Dave Whelan's Multifaceted Career and Contributions01:18:04 Key Mistakes in Health Tech Innovation

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, Matthew and Lindsay welcome Maynard Nexsen attorney James Childs, who leads the firm's private markets and private equity practice as well as the venture capital and emerging growth practice. In one of our most content-rich episodes to date, James offers a comprehensive look at the legal foundations every life sciences startup needs to understand, from formation to funding. With decades of firsthand experience, James breaks down critical topics including entity structure, intellectual property protection, securities law compliance, investor negotiations, and university licensing. Whether you're launching a biotech startup or preparing for a capital raise, this episode is packed with insights for long-term success. Listen now!

Join AFS Life Sciences Partner Stephanie Trunk and Darshan Kulkarni, Life Sciences regulatory and compliance attorney, to unpack the recent acceleration of mergers and acquisitions across the life sciences sector. They examine why deal flow is increasing, why buyers are favoring asset purchases over mega-deals, and how drug pricing and compliance priorities under the Trump Administration are shaping decisions. They also explore how rigorous due diligence can mitigate risk, where artificial intelligence (AI) may streamline diligence, and why intellectual property (IP) mapping to actual products remains a recurring gap. The discussion closes with practical insights on building a robust compliance culture and navigating an evolving health care enforcement landscape. Key Takeaways Include: - Increasingly, buyers favor strategic, targeted acquisitions over mega-deals. - Policy impacts from the Trump Administration influencing deal strategy. - Heightened due diligence emphasis on compliance and pricing risks. - Emerging role of AI to streamline due diligence workflows. - Persistent gaps in IP diligence, including weak mapping to products.

On this special segment of The Full Ratchet, the following Investors are featured: Barry Schuler of DFJ Growth Ventures Shashank Saxena of Sierra Ventures Jeff Bussgang of Flybridge Capital We asked guests to discuss the most visionary founder that they've worked with and what makes them so special. The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area. We're proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.   Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.

In this episode, hosts Payal Nanavati and Megan Beaver speak with Linda Malek and Matthew F. Ferraro about the latest federal and state developments in artificial intelligence (AI) policy affecting health care. The conversation covers the Trump administration's AI action plan and Executive Orders on AI, new industry-specific and comprehensive state laws, and enforcement trends, with a focus on how these changes impact the health care industry. This podcast episode features the following speakers: Linda Malek is a partner in Crowell & Moring's New York office, and is a member of our Health Care, Privacy & Cybersecurity, and Life Sciences practices. She advises a broad array of health care and life sciences clients on compliance with federal, state, and international law governing clinical research, data privacy, cybersecurity, and fraud and abuse. Linda also counsels digital health and biotech companies developing AI tools. She navigates the complex and evolving federal and state regulatory landscape, balancing the priorities of oversight authorities with issues related to data privacy and security as well as business goals. Matthew F. Ferraro is a partner in Crowell & Moring's Washington, D.C. office and is a member of our Privacy and Cybersecurity Group, where he advises leading organizations on high-impact matters involving artificial intelligence (AI), cybersecurity, and emerging technologies. He previously served as Senior Counselor for Cybersecurity and Emerging Technology to the Secretary of Homeland Security, helping shape national AI and cyber policy and helping to establish and run the Artificial Intelligence Safety and Security Board. Payers, Providers, and Patients – Oh My! is Crowell & Moring's health care podcast, discussing legal and regulatory issues that affect health care entities' in-house counsel, executives, and investors.

Erin Silva, Ph.D. https://cias.wisc.edu/directory/17158/FoA 280: Organic Farming Myths and Realities With Erin SilvaI wanted to invite Erin Silva back on the show to hear about her continued work with farmers that are going down the path of organic AND regenerative. On the surface, those two farming approaches are easy to get behind: let's try to reduce our dependence on synthetic chemistry and let's try to build soil health over time while still farming intensively and profitably. But in practice, there are tradeoffs. To promote more living roots on the soil through cover crops, as one example, farmers need a way to terminate those cover crops and using herbicides for that is really really helpful. So I'm intrigued about how farmers are making these systems work and how scientists like Erin our doing the critical research to understand how these practices can work on more acres for more farmers. So that is what today's episode is all about, and for context I'll give you a brief bio on our guest. Dr. Erin Silva is an Associate Professor and State Extension Specialist in Organic and Sustainable Cropping Systems in the Department of Plant Pathology as well as the Director for the Center for Integrated Agricultural Systems in the College of Agricultural and Life Sciences at UW-Madison. Her research influences the strong organic sector that contributes to Wisconsin's agricultural economy, with Wisconsin second only to California as the state with the greatest number of organic farms. In continued support of these farms and the organic sector within the state, nation, and globally, her research and scholarly contributions continue to be directed in the broad area of the biology and agroecology of organic crop management, with emphases on cover crops, soil health, and genotype/ environment interactions. Dr Silva earned her Ph.D. in Horticulture at Washington State University.

The following article of the Health industry is: “Mexico Cancels Drugs, Medical Devices Tender. What's Next?” by Juan Luis Serrano Leets, Partner Life Science, Garrigues.

Send us a textJoel Krikston is a seasoned executive with extensive experience in venture investments and strategic innovation within the healthcare sector.Joel currently serves as Managing Director Venture Investments Merck Global Health Innovation Fund ( https://www.merckghifund.com/?profile=joel-krikston ) and Co-Founder of MSD Idea Studios ( https://www.msd.de/ideastudio/ ), a global innovation hub organization that is committing $38 million to scale high-impact health technologies that directly align with Merck's access and R&D priorities. They are strategically located in the innovation hubs of Singapore and Berlin. With a career spanning over two decades, Joel has held pivotal roles at renowned organizations like Merck, Johnson & Johnson, and JPMorgan, focusing on biotechnology, corporate development, and health equity. As the Managing Director of Venture Investments and Head of Strategic Innovation Alliances, Joel excels in bridging the gap between life sciences and digital health technology. He is a recognized advocate for diversity and inclusion, emphasizing health equity in his professional endeavors. Joel's board engagements extend to various innovative healthcare startups, showcasing his commitment to shaping the future of healthcare. Joel also contributes to academia as a venture mentor and guest lecturer at prestigious institutions, including NYU Stern and Princeton University. Joel has an MBA from the Stern School of Business at NYU, completed his Bachelor's degree in Finance and International Business at Fairfield University, and has specialized certifications from Harvard and MIT, underscoring his dedication to ongoing learning and leadership in healthcare innovation.#JoelKrikston #MSDIdeaStudios #MerckGlobalHealthInnovationFund #InvestmentBanking #CorporateVentureCapital #LifeSciences #DigitalHealth #NYUStern #BNPParibas #ABNAMRO #InnovationHubs #LungCancer #VentureMentor #JohnsonAndJohnson #JPMorgan #BillTaranto #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

In this episode of Tiny Show and Tell Us, a listener writes in to tell us about being born 3 months premature likely due to their mom having HELLP syndrome, a variant of preeclampsia, and taking part in early trials for surfactants. Then we discuss why horseshoe crab blood is blue and the exciting generation of a one-electron bond between carbon atoms. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Xiong Liu, Director of Data Science and AI at Novartis. Novartis is among the world's leading pharmaceutical companies, pioneering data and advanced analytics in the pursuit of new medicines and patient outcomes. Xiong joins Emerj Editorial Director Matthew DeMello to examine how generative AI and foundation models are transforming R&D, clinical workflows, and research collaboration across the life sciences. The discussion highlights how domain-specific data strategies, improved data quality, and shared benchmarks are accelerating discovery and operationalizing AI for measurable ROI in biopharma. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Hans Clevers is hoofd Pharma Research and Early Development (pRED) bij Roche in Basel, Zwitserland.***Volg Leaders in Life Sciences via de website.Volg Leaders in Life Sciences via LinkedIn.Bezoek www.henkjanout.nl voor meer informatie over de host.***Vragen, suggesties of feedback? Graag! Stuur een email naar: henkjan.out@me.com***Vind jij de Leaders in Life Sciences podcast leuk? Dan zouden we het enorm waarderen als je een recensie zou willen achterlaten op Apple Podcasts of een vijf sterren beoordeling zou willen geven op Spotify.Jouw steun betekent veel voor ons, omdat het anderen kan aanmoedigen om de podcast ook te gaan beluisteren. Heel erg bedankt!***Leaders in Life Sciences wordt mede mogelijk gemaakt door Pivot Park, Pedersen & Partners en Johnson & Johnson Innovative Medicine.

Mazin Gadir, a regional expert in digital health strategy, Director with Alvarez & Marsal Healthcare and Life Sciences in Dubai, reflects on the Middle East's evolution from early EMR adoption to AI-driven healthcare. From Dubai's innovation playground to Abu Dhabi's depth in research, he explains how rivalry between Gulf states fuels progress and why exporting tested models to Africa and beyond is the new norm. He also questions the myth of leapfrogging, pointing out that fragmentation and lack of research remain barriers. This candid conversation explores regulation, interoperability, and the role of academia in sustaining innovation. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ 00:00 – Introduction: blockchain hype and digital health evolution 01:00 – From EMRs to health information exchanges in the Middle East 03:00 – The impact of COVID-19 on digital transformation 04:30 – Rise of patient empowerment and consumerization of healthcare 05:30 – The missing role of academia and research in the region 07:00 – Comparing Abu Dhabi and Dubai's different innovation models 09:00 – Dubai as a playground for testing, Abu Dhabi for research depth 10:30 – Rivalry across GCC states as a driver of innovation 12:00 – Exporting Gulf digital health models to Africa and beyond 14:00 – Challenges of scaling across Middle Eastern countries 16:00 – Interoperability: current maturity and pilgrim use cases 18:00 – Opportunities and limits of leapfrogging 20:00 – The role of academia and sustainability of innovation www.facesofdigitalhealth.com https://fodh.substack.com/

Life sciences organizations are facing both intense pressure and extraordinary opportunity, according to Mark Sullivan, president of regulated industries at Salesforce. In a conversation with The Top Line’s Chris Hayden, Sullivan said companies too often operate in “survival mode,” focused on defending margins rather than leading innovation. But with the rise of AI and agentic technologies, he said, the industry is poised for a transformation that could reshape how drugs are developed, trials conducted and patient data used — all at greater speed and lower cost. Sullivan emphasized that this new era requires rethinking how companies engage with stakeholders. Instead of distant, one-way interactions, he said, agentic AI enables dynamic, conversational relationships that improve satisfaction and generate actionable insights. Salesforce, he noted, is expanding beyond its CRM roots to help life science enterprises become “agentic” organizations — integrating secure, compliant AI systems across finance, HR and supply chains. With data security and trust at the core, Sullivan called on leaders to look beyond software replacement and pursue true digital transformation for the good of patients and the industry alike.See omnystudio.com/listener for privacy information.

In this 5 in 5 episode, I breaks down five key lessons from Dominic Colenso, actor turned communication coach, on how to present and connect with impact in Pharma, Life Sciences, and Healthcare.Learn how to start with your audience, tell powerful stories, design smarter slides, and lead with emotion to inspire action.Perfect for professionals who want to communicate clearly, confidently, and persuasively.Watch on YouTube: https://youtu.be/ZKZs7FH1yHIListen on Apple Podcast: https://podcasts.apple.com/gb/podcast/hands-on-business-the-h-files-unlocking-growth/id1548129226

Dr. Dan Pardi is the Chief Health Officer at Qualia Life Sciences, where he leads education initiatives focused on advancing healthspan and optimizing peak performance. Qualia Life Sciences develops products rooted in complex systems science, a framework that recognizes the body's natural ability to self-regulate and heal. Their growing product line includes support for brain health, cellular health, NAD+ levels, and most recently, Stem Cells.Dr. Pardi holds a PhD in Cognitive Neuroscience from Leiden University and Stanford. His work is dedicated to translating cutting-edge scientific research into practical tools and programs that help people live longer, healthier, and higher-performing lives. SHOWNOTES:

Almost a third of employees in Clare failed to take their full annual leave entitlements last year. A new report from FRS recruitment shows 31% of workers in this county did not use their full allocation of holidays in 2024. The survey also found that 2 in 5 people affected were not able to carry days over. Head of Technical Engineering & Life Science at FRS Gwen Leydon says staff often feel guilty about taking time off.

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Mathias Cousin, Managing Director at Deloitte. With extensive experience in R&D transformation and regulated industry data strategy, Mathias joins Emerj Editorial Director Matthew DeMello to unpack what it really takes for enterprise leaders to deliver ROI from AI and data initiatives. Mathias also shares actionable guidance on building effective “string of pearls” use cases, investing in data quality and AI-native talent, and adopting practical change management to embed AI in workflows for measurable gains in efficiency and long-term competitive edge. This episode is sponsored by Deloitte. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

For thousands of years, the rise and fall of empires and the global economy were closely tied to something you might not expect: spices. The spice trade began around 1000 BCE, localized to southeast Asia and the Middle East. But by the beginning of the next millennia, it had rapidly expanded and nations vied to control it. Today it's typically far less work to find and purchase spices you want, but just because they're no longer starting wars that upend nations doesn't mean they're any less important. Because while you might think spices are mostly about making your food taste good, science — and particularly chemistry — is finding they can do a whole lot more.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Investing in health and science research isn't just about curing diseases. It has huge impacts across society, from creating jobs to driving economic growth to boosting national competitiveness. Study shows that every $ invested in the life sciences industry generates $3 in GDP globally, whereas every job created in the life sciences industry generates five in the global economy. Life sciences are one of the most powerful engines of prosperity, yet many governments still underestimate their economic return.In this episode of The Ripple Effect: Investing in Life Sciences, host Dan Riskin speaks with Patrick Horber, President of Novartis International, and David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard. Together, they break down the outsized economic impact of life science innovation, from trillions in US bioscience output to China's meteoric rise as a global R&D hub. The conversation delves into the ways governments can support innovation with not just money, but through policy and regulation; plus, some of the best ways that countries can help the sector secure investment, talent, and long-term growth.This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Host: Dan RiskinGuests: Patrick Horber, David Gluckman  Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For the first time in decades, a major innovation in reproductive health is on the horizon. In this episode of StartUp Health NOW, StartUp Health community member Dr. Darlene Walley, CEO of NEXT Life Sciences, joins Unity Stoakes to discuss Plan A™, a long-acting, non-hormonal, fully reversible male contraceptive that could reshape how couples share family planning. Dr. Walley explains how Plan A works as a medical device, the company's global license for Vasalgel®, and the breakthrough results from 100% successful delivery device trials across two continents. With FDA-approved development plans and growing clinical momentum, the company is on track to submit for approval by 2027. Beyond science, this conversation explores a cultural shift: how men are stepping up to share responsibility for contraception and how this innovation could expand access, improve preventive care, and strengthen relationships worldwide. Listen in for a look at the future of men's health, reproductive equity, and one of the most anticipated breakthroughs in medical innovation. Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot PRO Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

Investing in health and science research isn't just about curing diseases. It has huge impacts across society, from creating jobs to driving economic growth to boosting national competitiveness. Study shows that every $ invested in the life sciences industry generates $3 in GDP globally, whereas every job created in the life sciences industry generates five in the global economy. Life sciences are one of the most powerful engines of prosperity, yet many governments still underestimate their economic return.In this episode of The Ripple Effect: Investing in Life Sciences, host Dan Riskin speaks with Patrick Horber, President of Novartis International, and David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard. Together, they break down the outsized economic impact of life science innovation, from trillions in US bioscience output to China's meteoric rise as a global R&D hub. The conversation delves into the ways governments can support innovation with not just money, but through policy and regulation; plus, some of the best ways that countries can help the sector secure investment, talent, and long-term growth.This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Host: Dan RiskinGuests: Patrick Horber, David Gluckman  Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Crystal Phillips, former Olympic-level speed skater and co-founder of the Branch Out Foundation, joins Collisions YYC as the newly minted Senior Director at the Opportunity Calgary Investment Fund (OCIF). In this candid and future-forward episode, Crystal and host Tyler Chisholm explore how OCIF is fueling Calgary's transformation through strategic investments in high-potential sectors—from life sciences to agtech to creative industries. Crystal unpacks how OCIF evaluates projects for impact, fosters ecosystem “collisions,” and balances long-term vision with short-term execution. She also shares personal insights on leadership, navigating imposter syndrome, and why Calgary's culture of collaboration remains its greatest asset. This episode is a masterclass in economic development meets emotional intelligence. A must-listen for entrepreneurs, investors, and civic leaders alike.Topics Covered:What OCIF is and how it worksSector-focused economic development (Life Sciences, Agtech, Aerospace, etc.)Creating and funding hubs, nodes, and platformsThe balance of curiosity vs. decision-making in leadershipWhy creative industries are crucial to ecosystem storytellingNavigating imposter syndrome in new rolesCalgary's innovation ecosystem and its unique strengthsFor the extra curiousLinks & Mentions:Opportunity Calgary Investment Fund (OCIF) Branch Out Neurological Foundation Platform CalgaryThe Knowledge SocietyCreative Destruction LabSimilar episodes you might enjoyE515 – Justin Caskey, Transforming Service Business With Technology E512 – Chris Foster, AI Hype vs. Reality: Expert InsightsE500 – Deborah Yedlin, Brains, Business, and Belonging: Unpacking the Calgary AdvantageE513 – Rosa Twyman, Energy Markets, Renewables, and Consumer Impact E495 – Leah Sarich, Exploring the Human Side of Startup Success and ChallengesThis episode is brought to you by clearmotive marketing. When it comes to marketing that truly matters to your business, clearmotive is your go-to partner. With a proven track record of more than 15 years, they understand what makes your business tick. Learn more at https://www.clearmotive.ca and discover how clearmotive can help your marketing thrive.We're on social media! Follow us for episodes you might have missed and key insights on Western Canada directly on your feeds.Instagram: https://www.instagram.com/collisionsyycLinkedIn: https://www.linkedin.com/company/collisions-yycYouTube: https://www.youtube.com/@collisionsyycWebsite: https://www.collisionsyyc.comThank you for tuning into Collisions YYC!Remember to subscribe and follow us on Spotify and Apple Podcasts so you never miss an episode.If you loved the episode, please leave us a 5-star review and share the show with your friends! These things really help us reach more potential fans and share everything that's amazing about Western Canada.We sincerely appreciate your support of our local podcast.Host links:Tyler's website: https://www.tylerchisholm.comTyler's LinkedIn: https://www.linkedin.com/in/tylerchisholmGuest links:Crystal Phillips' LinkedIn: https://www.linkedin.com/in/crystal-phillips-7296b932OCIF's Website: https://www.opportunitycalgary.com/Collisions YYC is a Tyler Chisholm original production // Brought to you by clearmotive marketing

In this episode of BioTalk with Rich Bendis, Harry Coker, Jr., Secretary of the Maryland Department of Commerce, joins the podcast to discuss Maryland's rising momentum as a global biohealth and technology leader. Secretary Coker shares his unique journey from the CIA, NSA, and White House to leading Maryland's economic development strategy, highlighting the state's strengths in life sciences, its appeal to global investors, and the importance of public-private partnerships in accelerating innovation.   Topics include Maryland's recent recognition as a Top 3 biopharma hub, the decision to prioritize Life Sciences and Computational Biology as “Lifehouse” sectors, and how the state is leveraging the BioHealth Capital Region identity to unite and expand its regional leadership. He also outlines Maryland's case for investment and why collaboration will be central to "Winning the Decade."   Editing and post-production work for this episode was provided by The Podcast Consultant.   The Honorable Harry Coker, Jr. was appointed by Governor Wes Moore as Maryland's Secretary of Commerce in 2025. He is a retired senior executive from the CIA and NSA, former National Cyber Director at the White House, and a career Naval Officer. Coker's leadership is shaped by decades of public service at the highest levels of national security and technology. At the Maryland Department of Commerce, he leads efforts to build an equitable, competitive economy centered around innovation, inclusion, and impact.

  AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S06 EP19 (281) 10-12-2025   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2025 - Oct. - 5 Days Talks, Events & Awards AZ Advances - nonprofit donation to biotech startups Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus     Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.         AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Notes:   Seg 1   Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion.   Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024.   AZ Bio Science Week started in 2017. AZ Bio week starts Oct. 13 (2025) and has events daily from Monday to Friday.     Example of one of the many companies involved with AZ Bio week:   CND Life Sciences - CND's Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.   NIH - National Institute of Health gives grants or funding to universities, hospitals and even companies for medical research.   Takes time to build a medical device type product, a few years to decades.   Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help.  $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy. Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory.  Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today. Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years.   Creation of the Covid vaccine was an outlier, as many people had Covid at the time so it was very easy to put together big study groups       Seg 2   Examples of newer companies in biotech field –   Neo clinical stage company dealing in heart health with aortic artery for the abdomen.   Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages.   Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control.       AZ Bio has members that are in the bioscience industry with current companies   AZ Advances is about bio startups in early stage companies It's a 501 C nonprofit charity that is funding, internships, and education   Patient is not only the client, but the purpose for why biotech companies exist     Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces. It was founded by Elon Musk and a team of eight scientists and engineers. Neuralink was launched in 2016 and first publicly reported in March 2017.   Neuralink's first human patient, Noland Arbaugh, is an Arizona native who received his implant in January 2024 at the Barrow Neurological Institute in Phoenix. He will appear at Arizona Bioscience Week 2025     https://www.azbio.org/azbw2025     Events Summary:   Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tuesday - Fundraising Fundraising Strategies for Life Science Startups  A compelling narrative is crucial when you are fundraising and communicating with life science investors.  This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup.      Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 21st Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards.   Thursday -  AZAdvances   AZ Advances Health Innovation Summit This exclusive event will bring together health innovation leaders to share how are moving Arizona forward as we make life better for the people we serve.   AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come.  Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations.    Friday - Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.        Seg. 3 Best of AZ Bio clips:   AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 4 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE           Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

In this episode of Tiny Show and Tell Us, we get to the bottom of if glass is a liquid or a solid and why riboflavin makes milk fluorescent. Then we talk about the Laser Interferometer Space Antenna (LISA) — the first space-based observatory that NASA scientists and their collaborators are sending up into space to detect and study gravitational waves, better known as “ripples in spacetime.” We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Lab Rats to Unicorns, John Flavin is joined by Todd Manjuck—Associate on JPMorgan's Innovation Economy team and former U.S. Navy SEAL. Todd supports venture-backed companies across the life sciences sector, helping founders and executives navigate the unique challenges of scaling healthcare businesses. From capital access to operational strategy, Todd serves as a connector between early-stage innovators and the broader ecosystem. Before entering the world of finance and innovation, Todd spent over eight years as a Navy SEAL, an experience that continues to shape his approach to leadership, resilience, and decision-making under uncertainty. He reflects on how lessons from special operations translate to biotech—whether in adapting strategy, managing risk, or building strong teams. Throughout the conversation, Todd shares his perspectives on today's life sciences landscape, the parallels between entrepreneurship and combat training, and the importance of mentorship and resilience in the face of uncertainty. He also opens up about his mother's cancer journey, which inspires his commitment to supporting companies working to advance treatments and improve patient outcomes.

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When it comes to the topic of drug discovery and development, scientists are busy furrowing their lab-goggled brows trying to understand what's real and what's hype when it comes to the power and potential of AI. This *Resonance Test* conversation perfectly dramatizes the situation. In this episode, Emma Eng, VP of Global Data & AI, Development at Novo Nordisk, and Chris Waller, EPAM's VP of Scientific Informatics Consulting and Chief Scientist in Life Sciences, provide a candid view of drug development in the AI era. “We're standing on a revolution,” says Eng, reminding us that “we've done it so many other times” with the birth of the computer and the birth of the internet. It's prudent, she cautions, not to rush to judgement guided by either zealots or skeptics. Waller says, of the articles about AI and leadership in *Harvard Business Review,* one could do “a search and replace ‘AI' with any other technological change that's happened in the last 30 years. It's the same kind of trend and processes and characteristics that you need in your leadership to implement the technology appropriately to get the outcomes that you're looking for.” Which means, for pharma, much uncertainty and much experimentation. “I think experimentation is good,” says Eng, who then adds that we need to always keep track of what is it that we're experimenting on. She says that the word “experimentation” can “sound very fluid” but in fact, “It's a very structured process. You set up some very clear objectives and you either prove or don't prove those objectives.” Waller references the various revolutions (throughput screening, combinational chemistry, data, and analytics revolutions) that pharma has seen and says: “We've all held out hope for each and every one of these revolutions that the drug discovery process is going to be shrunk by 50% and cost half as much. And every time we turn around, it's still 12 to 15 years, $1.5 to $2 billion.” Will AI make the big difference, finally? “Maybe we need to be revolutionized as an industry,” she says. “It can be hard to make much of a difference as long as there are few big players.” Just a few big players, she says, is “the nature of pharma.” Of course, our scientists are measured in their assessments about industry change. After all, as Waller says, the systems involved—the human body, the regulatory environment, the commercial ecosystems—are all “super-complicated.” Eng notes that an important side-effect around the AI hype is corporate interest in data. “Now it's much easier to put that topic on the table saying, ‘If you want to do AI, you need to take care of your data and you need to treat it like an asset.'” Listen on as they test topics such as regional and regulatory challenges in AI adoption, change management, and future tech and long-term impact (watch out for quantum, everyone!). In the end, Eng returns to the idea of revolutions. “You think you want so much change in the beginning which you don't get because it takes time,” says Eng. This makes us underestimate what will happen later. Having such a farseeing mindset is significant, she says, because “these technology shifts will have a large impact on the long term.” Host: Alison Kotin Engineer: Kyp Pilalas Producer: Ken Gordon

Meet Dr. Bo Wen, a staff research scientist, AGI specialist, cloud architect, and tech lead in digital health at IBM. He's joining us to discuss his perspective on the rapid evolution of AI – and what it could mean for the future of human communication… With deep expertise in generative AI, human-AI interaction design, data orchestration, and computational analysis, Dr. Wen is pushing the boundaries of how we understand and apply large language models. His interdisciplinary background blends digital health, cognitive science, computational psychiatry, and physics, offering a rare and powerful lens on emerging AI systems. Since joining IBM in 2016, Dr. Wen has played a key role in the company's Healthcare and Life Sciences division, contributing to innovative projects involving wearables, IoT, and AI-driven health solutions. Prior to IBM, he earned his Ph.D. in Physics from the City University of New York and enjoyed a successful career as an experimental physicist. In this conversation, we explore: How Dr. Wen foresaw the AI breakthrough nearly a decade ago The implications of AGI for communication, reasoning, and human-AI collaboration How large language models work. What AI needs to understand to predict words in sentences. Want to dive deeper into Dr. Wen's work? Learn more here! Episode also available on Apple Podcasts: http://apple.co/30PvU9C

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 1856, after yet another day of disappointing experiments, a chemist named William Henry Perkin was cleaning up his glassware when he made a discovery that would harken a new — and colorful — era of science and industry. Just 18 years old, Perkin was a promising young student in a prestigious lab at the Royal College of Chemistry in London and he was supposed to be figuring out a way to make a chemical compound called quinine. Despite his best efforts, Perkin was coming up empty — or rather — producing a lot of dirty dishes with little to show for it. But he did notice that there was a curious goop in one of his flasks, and it turned a brilliant shade of purple in the wash. Intrigued, Perkin decided to try dyeing a swatch of silk with his serendipitous solution. Although he had failed yet again to produce quinine, Perkin had created the very first synthetic dye and launched a scientific industry that is still bringing new drugs and dyes to market today.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Professor Cougar Hall sits down with Greg Hooke, a senior in Public Health and member of the College of Life Sciences Student Belonging Council, to explore what “belonging” really means at BYU—and how simple acts of connection can change campus culture. Greg shares how a Johns Hopkins internship studying bias in long-COVID care opened his eyes to everyday experiences of being unseen, and how that sparked student-led efforts at BYU: first-gen mentoring lunches, a Women in Life Sciences dinner, and hands-on service with Help Me Grow Utah and United Way. He and Dr. Hall unpack the tension between competition and collaboration in tough gateway classes, swap practical ways introverts and extroverts alike can make friends, and celebrate a college-wide bump in belonging (now ~86%). Greg also opens up about recovering from a traumatic brain injury, the faith that grounded him, and his goal to become a neurologist who blends clinical care with public-health principles of inclusion. If you're new to campus—or helping those who are—this episode is equal parts playbook and pep talk. Recorded, Edited & Produced by Christy Gonzalez, Harper Xinyu Zhang, Kailey Hopkins, and Tanya Gale

In today's rapidly evolving business landscape, scaling enterprise sales teams presents unique challenges and opportunities. As the Chief Revenue Officer of Motive, Adam Block brings a wealth of experience in building high-performance sales organizations. In this episode, we explore effective strategies for scaling enterprise sales teams in the AI era.                   Scaling Enterprise Sales: Key Insights ·         Building a robust playbook for enterprise sales success ·         Implementing effective hiring and onboarding processes ·         Leveraging AI and technology to enhance sales efficiency ·         Developing a strong sales culture and team dynamics The Power of People in Scaling Sales One of the core themes Adam emphasizes is the importance of hiring and developing top talent. He outlines: A comprehensive interview process, including panel interviews Assessing candidates' resilience, accountability, and discipline Creating a "farm system" for developing sales talent internally Develop Clear Playbooks Adam outlined three crucial elements of effective sales playbooks: Product knowledge - Understanding what you sell and how it impacts customers Clear expectations - Outlining exactly what's expected in each role Unified approach - A consistent philosophy for engaging prospects Boosting Seller Efficiency and Pipeline Growth Adam provides practical strategies for improving sales performance, including:                          ·         Focusing on pre-hello activities to secure initial conversations ·         Utilizing AI for account research, territory planning, and meeting assessments ·         Balancing technology with human touch in the sales process The Role of AI in Modern Sales While AI is transforming many aspects of sales, Adam cautions against over-reliance: ·         AI tools for enhancing productivity and insights ·         The continued importance of human connection in sales ·         Balancing AI automation with personalized outreach This episode offers a comprehensive look at scaling enterprise sales teams, blending time-tested strategies with cutting-edge AI applications. Whether you're a sales leader looking to grow your team or a sales professional aiming to enhance your skills, you'll find actionable insights to elevate your sales game. Key Moments 00:00:00 - Effective Sales Strategies for Market Contact 00:00:42 - Introduction to Adam Block and Motive 00:04:32 - Adam Block's Guilty Pleasure: 80s Music 00:07:19 - Scaling Enterprise Sales Organizations 00:15:36 - Finding and Assessing Top Sales Talent 00:20:58 - Panel Interview Process for Sales Candidates 00:32:46 - Boosting Seller Efficiency and AI Integration 00:47:50 - Closing Thoughts and Career Opportunities at Motive About Adam Block Adam oversees Motive's global Revenue and Go-To-Market functions, including sales, business development, strategy, operations, sales engineering, and partnerships. Prior to Motive, he served as Vice President over the Public Sector, Healthcare, Manufacturing, High Tech, and Life Sciences teams at Medallia, the leading enterprise experience platform. During his tenure, Medallia went public and was later acquired for $6.4B. Before Medallia, Adam was Vice President, Sales and Marketing for TenMast software (now MRI software) and previously served as Partner and Vice President of Sales at Zeta Marketing, an internet marketing startup. Adam earned his Bachelor of Business Administration (BBA) in Finance and Management from the University of Kentucky. Follow Us On: ·         LinkedIn ·         Twitter ·         YouTube Channel ·         Instagram ·         Facebook Learn More About FlyMSG Features Like: ·         LinkedIn Auto Comment Generator ·         AI Social Media Post Generator ·         Auto Text Expander ·         AI Grammar Checker ·         AI Sales Roleplay and Coaching ·         Paragraph Rewrite with AI ·         Sales Prospecting Training for Individuals ·         FlyMSG Enterprise Sales Prospecting Training Program Install FlyMSG for Free: ·         As a Chrome Extension ·         As an Edge Extension  

In this episode of Tiny Show and Tell Us, a listener on “team wasp” writes in with some interesting info on USDA wasps for pesticide-free pest control and we learn about some wasp versus beetle drama. Then we talk about how our red blood cells use and expel iron, and how a huge percentage of the iron we get is from broken down blood cells.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

在世界與美國情勢及相應政策皆加劇動盪的年代，身為在美國科學界的學人們是如何因應呢？這次我們邀請了在美國聖路易華盛頓大學基因體與遺傳學系的金聖智教授一起來聊聊我們成長路上直到2025年6月的大事件，以及在大環境的變遷下大家都是怎麼自處的。原來我們一路上也度過了好多動盪的時刻，或許這就是成長路上必須不斷學習的課題吧？ 相關連結 Faculty Spotlight Jin Lab 工作人員 內容製作：雯薇、Angel、Peter 後製：雯薇 文案：雯薇 音樂：雯薇 封面：雯薇 上架：雯薇 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

Vediamoci! Il 24 settembre, alle 18:00 siamo alla Triennale di Milano per un nostro live podcast!

Send us a textIn this episode of the Life Science Success Podcast my guest is Josh Yelen, a CPA, MBA, and the Founder & CEO of Function, a strategic financial leadership and bookkeeping services company that supports businesses across various industries, including life sciences. With over two decades of experience in operations, accounting, finance, and sales, Josh is also a co-founder of Venture Forward Capital, where he supports early-stage entrepreneurs in building disruptive companies.00:00 Introduction to Life Science Success Podcast00:40 Join Our Free School Community01:41 Introducing Our Guest: Josh Yelen02:10 Josh Yelen's Professional Journey04:30 The Birth of Venture Forward Capital and Function09:05 Function's Unique Approach to Financial Services14:55 Challenges in Biotech and Pharma20:40 Trends Shaping the Future of Biotech29:19 Firing the Biggest Client and Growing the Business29:46 Innovative Use of AI in Business30:53 Aligning Company Goals with OKRs32:45 The Importance of Focus and Avoiding Distractions36:46 Leadership Advice and Entrepreneurial Challenges39:31 Motivational Videos and Personal Drive45:37 Concerns About AI and the Future of Work50:48 Excitement for the Future and Final Thoughts

Back in April, a company called Colossal Biosciences announced that they had brought dire wolves — ancient canines of Game of Thrones fame — back from extinction. The internet went wild. But while some media outlets proclaimed the return of a long-gone species, many scientists shot back on social media that these weren't really dire wolves, they were just genetically engineered grey wolves. Suddenly everybody had an opinion on what de-extinction is, what it is not, and whether or not we should be doing things like this in the first place. In this episode, we talk to scientists who have been working in this area for a while, and they not only share their thoughts on these wolves — they completely change our understanding of the term “de-extinction.”Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"Every community has different values, and every community should have different choices. And that's why local food is so important so that local communities and local farmers can decide what's most important to them and how they want to connect the people who grow our food with the people who are seeking nourishment." —Andy Naja-Riese "The health of our Farmers Market is really dependent upon the health of our farmers." —Tanner Keys   Wonder why local food sometimes costs more, or if it's really worth the effort to shop there? The real story behind farmers' markets is more complicated—and more important—than you might think. Andy Naja-Riese, CEO of the Agricultural Institute of Marin, and Tanner Keys, Cooperative Agreement Manager for the Islands of Remote Areas Regional Food Business Center, have spent years on the front lines of food access. Their work in California and Hawaii gives them a unique view on what it takes to make local food affordable, how certification and regulations shape what you see at the market, and why these markets matter for everyone. Listen in for honest talk about food prices, local farming, organic rules, food as medicine, and how farmers' markets are working to make healthy food available to all. You'll get practical insights, real solutions, and a fresh look at what's possible in your own community. Meet Andy: Andy Naja-Riese brings 17 years of experience in community food systems, public health, and food equity programs & policy. As Chief Executive Officer, he leads AIM's major programs, partnerships, strategic planning, advocacy, and fundraising, including a capital campaign for AIM's Center for Food and Agriculture in collaboration with AIM's Board of Directors. Andy joined AIM in 2018 after spending 10 years working for the Federal government, including the U.S. Department of Agriculture's Food and Nutrition Service.  Andy is currently the Co-Chair of the Marin County Healthy Eating Active Living (HEAL) Collaborative, serves on the Steering Committees of the Marin Carbon Project and Marin Community Health Improvement Plan, sits on the National Farm to School Network's Advisory Board, and represents AIM on the California Food and Farming Network & Food and Farm Resilience Coalition. He received the 2022 CVNL Heart of Marin Award for Excellence in Leadership and the 2023 Farmers Market Champion of the Year award from CAFF. He earned his master's degree from the T.H. Chan Harvard School of Public Health and his bachelor's degree from Cornell University's College of Agriculture and Life Sciences.  He lives with his husband and dog in Sonoma, where he enjoys backyard gardening, cooking farmers market hauls, eating bagels, and enjoying Northern California's natural beauty Website Facebook X Instagram LinkedIn YouTube   Meet Tanner: Tanner Keys grew up in an agricultural community & lifestyle that has instilled a passion for food & land. He has served in various roles with the Hawaiʻi Good Food Alliance (HGFA) beginning in 2022, helping the organization in its beginning years and later leading a project of HGFA, the Hawaiʻi Farmers Market Association. Before that, he served as the Team Leader to the FoodCorps Inc., an AmeriCorps program, from 2019 to 2021. Tanner has a B.S. in Business Administration from the University of Oregon, and it was his service in the Peace Corps (Timor-Leste ʻ16-ʻ18) that led him back to the path of supporting agriculture & food security. LinkedIn Connect with Hawai'i Good Food Alliance Website Instagram Facebook   Connect with NextGen Purpose: Website Facebook Instagram LinkedIn YouTube   Episode Highlights: 01:16 Geography and Food Access: How Location Changes Everything 06:13 Comparing Coasts: East vs West Market Experiences  10:38 Organic vs Certified— What “Certified” Really Means  16:53 Hawaii and California's Diversity  23:40 Making Markets Accessible  27:55 Permanent Market Dreams: Building for the Future  33:57 Are Farmers' Markets Expensive? The Real Price of Local Food   Resources: Podcast S5 Ep 27: AIM— Preserving the Farmer's Market for Everyone with Andy Naja-Riese Part 2S7 Ep1: Boosting a Healthy, Accessible Local Farm-to-Table Revolution with Andy Naja-Riese Part 2

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Many supplements claim to “boost” your immune system. Now, we all want to avoid getting sick during the winter months, but do any of these products really work? And is trying to “boost” your immune system even a good idea? Jonathan speaks with Professor Daniel M. Davis, MBE — a leading expert on immunology and Head of Life Sciences at Imperial College London. Daniel has published 145 scientific papers, authored four best-selling science books, and spent 25 years researching how our immune system works. He even helped discover the immune synapse, a breakthrough that changed our understanding of immunity. Daniel explains how your immune system really works, why it's connected to mental health, and how it can even detect cancer cells. He also clears up common myths and shares what genuinely helps keep your immune system strong through the winter months — and what won't make a difference. By the end of the episode, you'll know the practical, science-backed steps you can take to reduce your risk of colds and flu this winter without wasting money on products that don't deliver. Unwrap the truth about your food

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.